Eye Care Associates Moves to Nextech
17 déc. 2024 09h00 HE
|
Nextech Systems, Inc.
Eye Care Associates of Northeastern Ohio has selected Nextech’s ophthalmic platform to automate workflows and improve the patient care experience.
EyeDNA Therapeutics Receives Rare Pediatric Disease Designation from FDA for its Investigational Gene Therapy HORA-PDE6b for Patients with Retinal Dystrophy due to PDE6b Gene Mutations
17 déc. 2024 06h00 HE
|
Coave Therapeutics
PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US Symptoms often start in childhood leading to blindness by midlife with no approved...
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
11 déc. 2024 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”),...
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
11 déc. 2024 07h02 HE
|
Ocugen
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Iantrek Announces Peer-Reviewed Publication Highlighting 12-Month Safety and Effectiveness Results for its Bio-Interventional Uveoscleral Outflow Technology in Open-Angle Glaucoma Patients
10 déc. 2024 08h00 HE
|
Iantrek, Inc.
White Plains, Dec. 10, 2024 (GLOBE NEWSWIRE) -- White Plains, NY – December 10, 2024 – Iantrek, Inc., a venture-backed, medical technology company pioneering next-generation bio- and...
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
06 déc. 2024 16h03 HE
|
NurExone Biologic Inc
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
04 déc. 2024 11h07 HE
|
VivaVision Biotech, Ltd.
VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following...
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
27 nov. 2024 07h09 HE
|
Ocugen
MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
India Contact Lenses Market Forecasts and Company Analysis Report 2023-2024 & 2032 Featuring Bausch & Lomb, Alcon Laboratories, J&J, Cooper Vision, Carl Zeiss, Hoya Medical, GKB Ophthalmic and Omni
25 nov. 2024 11h18 HE
|
Research and Markets
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "India Contact Lenses Market Report Forecast By Material, Design, Application, Distribution Channel, Region, States and Company Analysis" report has...
Middle East & Africa Ophthalmology Devices Market Forecast to 2031 - Regional Analysis by Product, Application and End User
25 nov. 2024 07h27 HE
|
Research and Markets
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Middle East & Africa Ophthalmology Devices Market Forecast to 2031 - Regional Analysis - by Product, Application, and End User" report has been...